Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

3.1 Inclusion Criteria To be eligible for this trial, patients must meet all of the following criteria: * Have confirmed acute, symptomatic, first lower extremity proximal DVT and/or PE that is NOT associated with a transient risk factor. * Have completed an initial treatment course of oral anticoagulant therapy for 3-12 months and have a recommendation from their provider to continue anticoagulation indefinitely. * Have the capacity to understand and sign an informed consent form. * Be 18 years of age and older. * Under the direct care of a healthcare provider for treatment of VTE for the length of time in the study. 3.2 Exclusion Criteria If a patient meets any of the following criteria, he or she may not be enrolled in the study: * Creatinine clearance (CrCl) \< 30 mL/min as determined by Cockcroft-Gault formula documented within 3 months from date of consent * Significant liver disease (Child-Pugh B or C) * Concomitant use of medications that are strong P-glycoprotein or CYP3A4 inducers/inhibitors * Another indication for chronic therapeutic-dose anticoagulation, such as atrial fibrillation (i.e., rivaroxaban, 10 mg daily, or apixaban, 2.5 mg twice daily, would not be appropriate therapy) * A clinical indication for a specific anticoagulant regimen (e.g., warfarin with a target INR of 2-3 is recommended for patients with 'triple-positive' antiphospholipid syndrome). * Life expectancy \< 3 months * Currently pregnant or breast feeding * Unable / unwilling to pay for one (or more) of the treatment options * Active Cancer defined as: Diagnosed with cancer within the past 6 months; or Recurrent, regionally advanced or metastatic disease; Currently receiving treatment or have received any treatment for cancer during the 6 months prior to randomization; or A hematologic malignancy not in complete remission • Unwilling / unlikely to agree to follow up